Form 8-K Amylyx Pharmaceuticals, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Amylyx Pharmaceuticals (AMLX) Sets List Price of $12,500 for 28-Day Supply of ALS Drug Relyvrio -- WSJ
September 30, 2022 8:49 AM EDTAmylyx Pharmaceuticals (NASDAQ: AMLX) Sets List Price of $12,500 for 28-Day Supply of ALS Drug Relyvrio -- WSJ
... More